Pre-challenge Evaluation of Immune Response in Serum Cytokines (Th1 and Th2) and T-cell Markers (CD4, CD8, CD3, and CD25) Following Administration of New Formulated Leishmania Vaccine in Balb/c Mice

Afshinéh Latifynia1*, Mohamad Hosein Niknam1, Samad Farashi Bonab1, Bita Ansari-Pour1, Zahra Gheflati1 and Mohammad Javad Gharagozlou2

1Department of Immunology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran
2Research Center for Immunodeficiencies, Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran

Abstract
Leishmaniasis is considered an endemic disease that is a major public health concern in Iran and elsewhere. It is suggested that an effective immune response against leishmaniasis is T-cell-mediated immunity that provides immunity against leishmania infection. The formulation and production of an immunogenic, effective, and safe vaccine to control leishmania infection is a necessity. Due to the complexity of the biological behavior of the leishmania parasite and its host immune response, the formulation and production of a safe and a protective vaccine is a difficult but worthwhile endeavor to tackle health problems.

Methods: In this study, we evaluated pre-challenged immune responses related to the Th1 (IFN-gamma and IL-12) and Th2 (IL-4 and IL-10) cytokine profiles, and the CD4, CD8, CD3, and CD25 markers of T cells. This measurement was followed by vaccination accompanied by two one-week interval boosters with the leishmania major antigen preparations adjuvant with BCG or alcoholic extract of Teucrium polium plant or both at 100 and 200 micrograms of the crude antigen/0.1 ml per mouse. This experiment was performed on six groups of leishmania-susceptible Balb/c mice.

Results: The statistical analysis of the data related to the T cells or lymphoid cells with the different markers, including CD8, CD3, and CD25, indicated that there were no significant differences between seven groups of animals; however, the differences were significant when the CD4 T cells were considered. On comparing the cytokines levels in the antigen-injected groups and the control group, the results showed only significant differences in serum IL-12 levels. Conclusion: It was concluded that, as shown in previous studies and the present research, the vaccine could not only induce a protective immunity in Balb/c mice, but also did not produce deleterious responses as shown through clinical monitoring and even resulted in a 100% survival rate of the experimental animals.

Keywords: New vaccine; Th1 and Th2 cytokines and CD4; pre-challenge; Balb/c

Introduction
There are three forms of leishmaniasis—namely cutaneous, visceral, and mucocutaneous. Leishmaniasis often occurs in areas where poverty, malnutrition, famine, and illiteracy are common. The disease is transmitted to vertebrate hosts by the bite of female phlebotomine sandflies [1]. Until now, an effective vaccine capable of controlling the leishmania infection by preventing cutaneous leishmaniasis has not been available, and it is speculated that one will be developed in the near future. Patients who have recovered from L. major infections develop high levels of immunity to the pathogen [2]. Leishmaniasis has a long history. Designs on pre-Colombian pottery and the existence of thousand-year-old skulls with evidence of leishmaniasis prove that the disease had been present in the Americas for a long time. It had also been present in Africa and India since at least the mid-18th century [3]. Today, there are an estimated 12 million cases of leishmaniasis worldwide with an estimated number of 1.5–2 million new cases occurring annually, which include 1–1.5 million cases of cutaneous and 500,000 of visceral leishmaniasis [1,4].

In vertebrate hosts, leishmania parasites survive and multiply as non-motile amastigotes, primarily in macrophages. The genus Leishmania comprises 30 species, of which around 20 are pathogenic for humans [5]. Sores can result in permanent scars and disfigurement. Treatment may reduce their severity. Medication can sometimes cure the disease; however, treatment is most effective when it is started before injuries enter the immune system. Visceral leishmaniasis often proves fatal within two years if it is not treated properly. For most species, humans are accidental hosts since leishmania is primarily a zoonotic disease [6]. Until now, a successful vaccination strategy against leishmaniasis has been limited to cutaneous leishmanization in which small doses of living virulent L. major promastigote are deliberately injected intradermally [7]. Since the mouse model is close to humans, it has been used for the study of both cutaneous and visceral leishmaniasis, but reflects the human cutaneous leishmaniasis rather than the visceral disease. Until now, several vaccine formulations have been prepared, but they were not found to be protective in primates [8,9]. That is why there is a need for new methods to assess the immune response of animals to vaccination that can better predict the response to virulent organism.

*Corresponding author: Afshinéh Latifynia, Department of Immunology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran. Tel: 982166432620; E-mail: alatifynia@sina.tums.ac.ir

Received: August 09, 2017; Accepted: November 30, 2017; Published: December 07, 2017

Citation: Latifynia A, Niknam MH, Bonab SF, Ansari-Pour B, Gheflati Z, et al. (2017) Pre-challenge Evaluation of Immune Response in Serum Cytokines (Th1 and Th2) and T-cell Markers (CD4, CD8, CD3, and CD25) Following Administration of New Formulated Leishmania Vaccine in Balb/c Mice. J Clin Cell Immunol 8: 533. doi: 10.4172/2155-9899.1000533

Copyright: © 2017 Latifynia A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
challenges in primates and humans. New methods would be useful for the detection of parasites as well as assessment by using pathological methods. The effective diagnosis of the progression of infection with my candidate vaccine will require an assessment of the genetic stability of the agent. The results obtained from the mouse model, although practical and informative, must be further confirmed in a primate model that more closely predicts pathogenesis and immunogenicity in humans [10]. The limitation of this unique alternative is that by default, the Th1/Th2 unique parameter of the mouse model is reflected on the leishmaniasis. In other words, compensating for the Th2 strategy of the parasite can be an effective alternative for the development of the vaccine against leishmaniasis instead of enhancing the Th1 response that occurs during the infection [11]. To date, two host systems have been classified for studying leishmaniasis infection on the basis of host susceptibility and resistance. This observation extends to the murine L. major model—for example, C57BL/6 mice being uniformly resistant and BALB/c consistently susceptible, which reflect the immune potentiality toward leishmania infection [12]. Dendrite cells (DCs) are potent antigen-presenting cells and can induce T cell activation efficiently [13]. It has also been shown that DCs are the source of different cytokines such as IL-12, IL-10, and IFN-γ [14-16].

The incubation of leishmania promastigote with dendritic cells can induce early IL-12 production in vitro, which might have originated from the preexisting pool of IL-12 p70 that was secreted soon after the ligation of any microbial product [17], suggesting the role of DCs in the initiation of T cell immune response in leishmania infection. It is also reported that the uptake of leishmania amastigotes by skin-derived DCs induces IL-12 p70, and up-regulates co-stimulatory molecules and vaccines against L. major infection. In marked contrast, L. major inhibits IL-12 production in macrophages [18,19]. IL-10 appears to constitute a major regulatory control in the outcome of infection, as well as the failure to produce IL-12 associated with the active form of the disease [20]. Our previous findings on the same newly formulated vaccine in two groups of mice (susceptible/Balb/c and (resistance/conventional) showed that it produced positive DTH [21] and led to an increase in white pulp size [22], which was statistically significant and correlated with effective immune responses, and was dependent on antigen doses, types of adjuvants, and injection groups [23]. Also, in other studies, our new formulated provisional vaccine was fortified with BCG and the allogeneic extract of the Teucrium polium plant as an adjuvant in Balb/c mice, and after that the vaccinated subjects were challenged with live promastigote that were harvested from the culture medium. In this experiment, Types 1 and 2 cytokines, spleen changes, and rate of survival were evaluated [24-26]. The findings indicated the safety, efficacy, and productivity of the new leishmania vaccine.

The aim of the present study is to further elucidate the effect of the new adjuvanted vaccine on the immune responses of Balb/c mice, pre challenge and post vaccination. In the present experimental design, we evaluated Th1 cytokines (IFN-gamma and IL-12) and Th2 cytokines (IL-4 and IL-10), and the markers belonging to T cell subtypes, including CD4, CD8, CD3, and CD25 markers, which are considered to be mostly involved in immune response against leishmania parasites and occur in the vaccinated animals.

Material and Method

Culture and isolation of Leishmania parasites

Leishmania parasites and antigens from the promastigote of the L. major (WHO) strain were provided by the Tehran University of Medical Sciences, and they were grown in NNN medium (14 g bacto peptone, 6 g NaCl, 300 ml rabbit blood, and up to 1200 mL H2O2) and in the second step were grown in RPMI 1640 culture, both FCS 5% and 10%. The harvested parasites were washed three times with normal saline solution (0.9%) or phosphate buffer saline (PBS). The parasites were counted in a Neubaur chamber and then kept at 70°C till use. After parasite accumulation in one flask, it was diluted to a concentration of 1.87 x 10^10.

For details of the procedure, please refer to the previous studies by Latifynia et al. [21-26]. In time, the harvested parasites were diluted to a concentration of 5.92 x 10^8 parasites per milliliter. Based on the previous studies, 100 μg/0.1 ml or 200 μg/0.1 ml Leishmania protein per dose of the provisional vaccine was selected for the formulation and preparation of the vaccine. The protein content of each dose was estimated by the Lowry method [27]. The vaccine was stored at 4°C until injection. BCG Vaccine (Mycobacterium bovis, Bacillus Calmette Gurine, BCG Strain Pasteur Institute of Iran, Frozen-dried BCG Vaccine Pasteur France, 1173 P2 secondary seed lot C, batch no. 179, Feb. 1995) was suspended and diluted in the SSI solution (125 mg MgSO4, 125 mg K2PO4, 1 mg L-asparagine, 12.5 mg iron ammonium citrate, 18.4 mg 85% glycerol, 0.5 mg citric acid, and 1 ml H2O for injection). The amount of BCG for each injection dose was 2 x 10^7 CFU/0.1 ml. To prepare the Teucrium polium adjuvant, 400 mg of alcoholic extract of Teucrium polium (28-30) was dissolved in 1 ml of distilled water; 2.5 mg/0.1 ml was used for each of the injection dosages of the antigen (100-200 μg/0.1 ml). The adjuvants were added to the leishmania antigen solutions mentioned previously, and two injection doses containing 100 μg/ml and 200 μg/ml of antigens supplemented with adjuvants were prepared.

Experimental design

Forty young adult female and male Balb/c mice were obtained from the Pasteur and Serum Research Institute, and they were randomly assigned to four standard polycarbonate boxes of four treatment groups. All the groups were fed ad lib with commercial mice kept in the polycarbonate boxes in a well-ventilated animal room located in the University of Medical Sciences of Tehran, School of Medicine, Tehran, and Islamic Republic of Iran. The experimental design consisted of six antigen-injected groups (LT 100, LT 200, LB 100, LT 200, LBT 100, and LBT 200) and a control group that received no antigen injection. Group LT received 100 or 200 μg/0.1 ml of the crude cocktail antigen plus BCG as adjuvant, Group LB received 100 or 200 μg/0.1 ml of the crude cocktail antigen plus BCG as adjuvant, Group LBT received 100 or 200 μg/0.1 ml of the crude cocktail antigen preparation plus alcoholic extract of Teucrium polium as adjuvant. The cocktail antigen preparation plus alcoholic extract of Teucrium polium and BCG as adjuvants. Groups LT, LB, and LBT were injected subcutaneously with the antigen preparations at the base of the tail. The control group did not receive antigen injection. All the six groups received a booster a week later. All the mice were scarified 25 days after the booster injection.

ELISA method

To evaluate cytokine levels in the sera of the animals, at most 2 ml of blood sample was taken from each mouse, and its serum was separated by using the routine standard method. The levels of IL-4, IL-10, IL-12, and IFN-γ in the six injection groups and the control group of mice were determined by the sandwich ELISA method according to the recommendations of the manufacturers. Mice serum levels of IL-4, IL-10, IL-12 and IFN-γ in the subjects were measured by using an automated micro plate reader set at 450 nm. The sensitivity limit was 20 pg/ml for IL-4, IL-10, and IFN-γ.
Spleen cell isolation and flow cytometry

Spleenic cells and lymphocytes were obtained from Balb/c mice by the collagenase method. Following this, 10^6 cells were treated with 4 mg/ml proteinase-free collagenase (Sigma-Aldrich, *C6079*) for 20 min at 37°C in saline solution at pH 7.5 under gentle agitation, followed by the neutralization of collagenase with an equal volume of complete RPMI media. The cells were centrifuged at 8000 g, re-suspended in saline solution containing 1% BSA, and passed through a 100 µm filter mesh before analysis. Negatively sorted CD4 T cells were obtained at higher than 90% purity according to FACS analysis by cell passage through mouse CD4 subset column kit (*MCD4C* according to the manufacturer’s instructions (R&D Systems Minneapolis, MN). DND3 T-cells were isolated either by depletion of CD4 and CD8 T-cells using tandem CD4 and CD8 mouse column kits (*MCD4C* and *MCD8C 1000, R&D Systems*), or by FACSAria cell sorter (BD, San Jose, CA) at 98% purity. For purification of DN, DP and SP4 T-cell subsets, single-cell suspensions were triple-stained with CD3 Ab-FITC, CD4 Ab-PE, and CD8 Ab-PerCP conjugates (BD Phar Mingen, CA) and then FACSort-sorted in three simultaneous windows in a FACSAria instrument. In some experiments, the TCRcd/NK cell depletion of FACSort-sorted DND3 spleenocytes was carried out by the incubation of cells with 2 µg/10^6 cells of anti-mouse TCRcd Ab-PE (clone #GL3, BD Phar Mingen, San Jose, CA) and 2 µg/10^6 cells of anti-asialo-GM1 Ab-PE conjugates (clone #SH34, ATCC), followed by incubation with anti-PE Abs coupled with magnetic beads and passage through MACS paramagnetic columns according to the manufacturer’s instructions (Miltenyi Biotech Inc., Auburn, CA) [28].

Data analysis and ethics

The data obtained from the experiments were analyzed by using SPSS (SPSS Inc., Chicago, IL, USA). The means were compared by the standard analysis of variance/simple factorial tests, and by one-and two-way student Newman Keuls methods. The correlation coefficient analysis was determined by a Pearson average two-tailed test of significance. The study was done in compliance with the Helsinki Declaration, and the protocol was approved by the research deputy of the Tehran University of Medical Sciences, Tehran, Iran.

**Table 1**: The results of analysis variance (ANOVA) for serum level IL-12, IL-4, INF-γ and spleen cell determinants: CD3+, CD8+, CD4+, and CD25+ between two injection doses (100 and 200 µg/ml) no considering to three injection groups (LB, LT, and LBT) and two injection doses (100 and 200 µg/0.1 ml) (*P<0.01*).

|                     | Sum of Squares | df     | Mean Square   | F       | Sig |
|---------------------|----------------|--------|---------------|---------|-----|
| **Interleukin 12**  |                |        |               |         |     |
| Between Groups      | 12232030.067   | 2      | 616105.033    | 8.081   | .001|
| Within Groups       | 26488453.472   | 35     | 756812.956    |         |     |
| Total               | 3872043.539    | 37     |               |         |     |
| **Interferon gamma**|                |        |               |         |     |
| Between Groups      | 18.571         | 2      | 9.286         | 2.341   | .110|
| Within Groups       | 146.765        | 37     | 3.967         |         |     |
| Total               | 165.336        | 39     |               |         |     |
| **Interleukin 4**   |                |        |               |         |     |
| Between Groups      | 0.34           | 2      | 0.17          | .694    | .506|
| Within Groups       | 9.15           | 37     | 0.25          |         |     |
| Total               | 9.50           | 39     |               |         |     |
| **Interleukin 10**  |                |        |               |         |     |
| Between Groups      | 2.719          | 2      | 1.360         | .541    | .587|
| Within Groups       | 92.978         | 37     | 2.513         |         |     |
| Total               | 95.697         | 39     |               |         |     |
| **Cluster Determinant 3** |          |        |               |         |     |
| Between Groups      | 593.168        | 2      | 296.584       | 2.686   | .117|
| Within Groups       | 1104.295       | 10     | 110.430       |         |     |
| Total               | 1697.463       | 12     |               |         |     |
| **Cluster Determinant 8** |            |        |               |         |     |
| Between Groups      | 18.508         | 2      | 9.254         | 2.196   | .158|
| Within Groups       | 46.362         | 11     | 4.215         |         |     |
| Total               | 64.869         | 13     |               |         |     |
| **Cluster Determinant 4** |          |        |               |         |     |
| Between Groups      | 552.505        | 2      | 276.253       | 2.910   | .097|
| Within Groups       | 1044.183       | 11     | 94.926        |         |     |
| Total               | 1596.689       | 13     |               |         |     |
| **Cluster Determinant 25** |          |        |               |         |     |
| Between Groups      | 1.270          | 2      | 0.635         | .901    | .434|
| Within Groups       | 7.755          | 11     | .705          |         |     |
| Total               | 9.025          | 13     |               |         |     |
12 increased, IL-10 decreased subsequently, and vice versa, when IL-10 increased, IL-12 decreased (Table 2).

**INF-γ:** The ANOVA test showed that the means square of INF-γ between the injection groups in comparison to the others (IL-12, IL4, IL10 and CD4+, CD8+, CD3+, and CD25+) showed no significant statistical differences (P=0.110), but their differences were very near to significant (Table 1). The amounts of INF-γ were as follows: LT 100>LBT 100 and LB 200=LBT 200>LT 200=Normal group. The highest amount was related to the injection dose of 100 µg/0.1 ml and the injection group LT (Tables 2 and 3; Figure 2). The highest level of IFN-γ (27.84 picogram/ml) was related to LT 100 µg/0.1 ml and the lowest IFN-γ to the normal group (without vaccine injection) (6.1 pg/ml<200 µg/0.1 ml [Table 2]). Pearson correlation was not significant at the 0.05 level with a two-tailed analysis (P<0.05) (Table 1). The correlation between two injection doses and normal groups with regard to IFN–γ and multiple comparison of IFN-γ with Tukey's HSD test and 95% CI showed no significant differences (P<0.005). Between two injection doses and control amounts were the following: 0 and 200 µg/0.1 ml (P=0.997), 100 and 200 µg/0.1 ml (P=0.125), 0 and 100 µg/0.1 ml (P=0.342), but 100 and 200 µg/0.1 ml was near to significant (Table 3).

**IL-4:** The ANOVA test showed that the means square of IL-4 between the injection groups in comparison to the others (IL-12, INF-γ, IL10 and CD4+, CD8+, CD3+, and CD25+) was not statistically significant (p=0.506) (Table 1). The amounts of IL-4 were as follows: LBT 100 µg/0.1 ml (2.84 pg/ml)>LT 100>LT 200=LB 100=LB 200 (1.96)>LBT 200 (1.6)>Normal (1.29) (Table 3; Figure 3).

The highest amount of IL-4 (2.84 pg/ml) was related to LBT 100 µg/0.1 ml and the lowest concentration was related to the normal group (1.29 pg/ml). The injection groups LB 100 and 200 µg/0.1 ml were equal (2.43 and 2.46 pg/ml) and LB 200 was 1.6 pg/ml.
Pearson correlation with a two-tailed test of IL-4 with IL-12 was 0.225 and not significant (p=0.174), but near to it. This means that both IL-12 and IL-4 can increase or decrease. In this context, there was no observed significant correlation between IL-4 and two injection doses (100, 200 µg/0.1 ml) with another measured cytokines and the other Th1 and Th2 measured cytokines and Cluster determinants (CDs) (Table 2). The results of multiple comparisons, Tukey's HSD test, and 95% CI between the two injection doses of 100 and 200 µg/0.1 ml were not significant at the 0.05 level (P<0.05).
Effects of provisional Leishmania Vaccine on spleen parameters, IL-12, IL-4, IFN-γ, IL-10, CD3+, CD8+, CD25+ and Survival Rates of the Female Balb/C Mice.

IL-12: Interleukin-12; IL-4: Interleukin-4; IFN-γ: Interferon-gamma; IL-10: Interleukin-10; CD3+: Cluster Determinant 3+; CD8+: Cluster Determinant 8+; CD25+: Cluster Determinant CD25+

Table 3: Effects of provisional Leishmania Vaccine on spleen parameters, IL-12, IL-4, IFN-γ, IL-10, CD3+, CD8+, CD25+ and Survival Rates of the Female Balb/C Mice.

| GROUP | Dosages Of Antigen µg/0.1 ml | Number of Balb/C mice | IL-12 pg/ml x¯ Min.-max. | IL-4 pg/ml x¯ Min.-max. | IFN-γ pg/ml x¯ Min.-max. | IL-10 pg/ml x¯ Min.-max. | CD3+ x¯ Min.-max. | CD8+ x¯ Min.-max. | CD25+ x¯ Min.-max. | Survival rates (percent) |
|-------|-------------------------------|------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-------------------|-------------------|-------------------|------------------------|
| LB    | 100                           | 6                      | 2462                     | 3941-65.5                | 1.96                     | 1.15-1.81                | 12.2              | 10.2-5.2         | 4.73              | 7.2-3.95               | 47.7                   | 46.6-48.8             | 15.6                | 14.9-16.3            | 35.5                | 30-41                 | 4.19                | 3.48-4.9              | 100%                |
| LT    | 100                           | 6                      | 2963.3                   | 3211.6-1898              | 2.43                     | 5-1.06                   | 27.84              | 70.4-7.6         | 4.22              | 5.2-3.66               | 48.5                   | 44.6-51.5             | 13.9                | 13.8-14              | 31.2                | 30.2-34               | 5.84                | 5.81-5.9              | 100%                |
| LBT   | 100                           | 6                      | 2353                     | 3896.3-1004              | 2.84                     | 4.9-1.2                  | 11.35              | 17.4-5.8         | 4.77              | 7.8-3.51               | 57                    | 57.9-56.1             | 19.35               | 18.7-20              | 37.05               | 36.5-37.6             | 6.61                | 6.41-6.8              | 100%                |
| LB    | 200                           | 6                      | 3688.3                   | 4303-2651.7              | 1.93                     | 2.7-1.1                  | 14.94              | 19.8-5.8         | 4.15              | 4.6-3.75               | 57.97                  | 46.2-78.9             | 16.33               | 12.8-18.5            | 37.13               | 32.3-46.4             | 5.18                | 4.3-6.3               | 100%                |
| LT    | 200                           | 6                      | 3010                     | 2196-3859                | 2.46                     | 7.4                     | 10.4-4.9          | 5.74              | 4.65              | 47.1842               | 14.3-19.9             | 13.9                | 31-63.9               | 5.75                | 5.34-6.2              | 100%                |
| LBT   | 200                           | 5                      | 3486                     | 3862-3079                | 1.6                      | 3-1.1                   | 9.9                | 16.4-5.6         | 5.7               | 12.6-3.8               | 72.83                  | 47.1-86.4             | 12.27               | 14.1-18.9            | 55.57               | 31.5-69.1             | 5.57                | 5.41-5.7              | 100%                |
| Control| 0                             | 5                      | 3896                     | 4262-3548                | 1.29                     | 1.5-1.2                 | 7.48              | 8.4-6.1          | 3.94              | 4.9-3.02               | 62                    | 51.3-72.7             | 15.23               | 13.4-16.2            | 47.2                | 37.6-58.1             | 5.39                | 5.0-5.7               | 100%                |

Mean within column with no common superscripts are significantly different (P<0.005)

IL-12: Interleukin-12; IL-4: Interleukin-4; IFN-γ: Interferon-gamma; IL-10: Interleukin-10; CD3+: Cluster Determinant 3+; CD8+: Cluster Determinant 8+; CD25+: Cluster Determinant CD25+

IL-10: The ANOVA test showed that the means square of Th2 cytokine (IL-10) between the injection groups and in comparison to others (IL-12, INF-γ, IL-4 and CD4+, CD8+, CD3+, and CD25+) showed no significant statistical differences (p=0.306) (Table 1). The amounts of IL-4 were as follows: Normal group (1.29 pg)<LBT 200 µg/0.1 ml (1.6 pg)<LB 100=LB 200 (1.96 pg)<LT 100=LBT 200 (2.46)<LBT 100 (2.84) (Table 3; Figures 4 and 5). The highest level of IL-10 was related to LBT 100 µg/0.1 ml (5.7 pg/ml), and the lowest concentration was related to the control group (1.29 pg/ml). The results also showed that the mean of IL10 for the two injection doses 100, 200 µg/0.1 ml and 0.00 µg/0.1 ml (control), while considering the group injection in the serum of Balb/c mice after vaccination with the new leishmania vaccine with 95% CI, showed that the doses of 100 and 200 µg/0.1 ml had no significant differences with each other, but had significant differences with the 0.00 injection dose (see Graph 3; Figures 4 and 6).

Cluster determinant 3 (CD3+): The ANOVA test showed that the means square of Th2 cytokine (CD3+) between the injection groups and compared to the others (IL-12, INF-γ, IL-4, IL-10, CD4+, CD8+, and CD25+) was not significant, but very near to it (P=0.117) (Table 1). The amounts of CD3+ were as follows: Normal group (4303-2651.7)=LT 100=LB 100=LB 200=LT 200 (4.9)=LBT 100=LB 200 (5.7)≥Normal (5.4)≥LT 100 (5.2)≥LB 100 (5.18)≥LB 200 (5.18)≥LBT 100 (5.18)≥LBT 200 (5.18)≥Normal (5.18) (Table 3; Figures 4 and 5). The highest level related to LBT 200 and the lowest was related to LB 100 and LT 100. Pearson correlation with a two-tailed test of CD3+ with level was related to LBT 200 and the lowest was related to LB 100 (0.958), with CD8+ (0.367), IL-12 (0.958), and IFN-γ (0.303) were relatively high but not significant, and with
Cluster Determinant 8 (CD8+): The ANOVA test showed that the means square of Th2 cytokine (CD8+) between injection groups and compared to others (IL-12, INF-γ, IL4, IL-10, CD4+, CD3+, and CD25+) had no significant statistical differences but were very near to it (P=0.158) (Table 1). The amounts of CD3+ were as follows: LB 200 µg/0.1 ml (12.27 pg)<LT 100 (13.9)<control (15.23)<LB 100 (15.6)<LB 200 (16.43)<LBT 100 (19.35) (Table 3; Figure 5). Among the injection groups, CD8+ did not show statistical differences (P=0.158), which was not significant (Table 2), but very near to it. The highest amounts were related to LB 200 and the lowest was related to LBT 100 (Table 3). Pearson correlation with a two-tailed test on CD8+ with doses of 100 and 200 µg/0.1 ml (0.490) and 0.075 significance revealed relatively high results but not significant ones.

Cluster Determinant 4 (CD4+): The ANOVA test showed that the means square of Th2 cytokine (CD8+) between the injection groups and compared to the others (IL-12, INF-γ, IL4, IL-10, CD8+, CD3+, and CD25+) had significant statistical differences, and were very near to it (P=0.097) (Table 1). The amounts of CD3+ were as follows: LT 100 µg/0.1 ml (32.1 pg)<LB 100 (35.5)<LBT 100<LB 200<LT 200 (41.2)<control (47.2)<LBT 200 (55.57). The highest level was related to LBT200 and the lowest was related to LT100 (Table 3). Pearson correlation with a two-tailed test of CD4+ with CD3+(0.958) and 0.000 significance, with doses of 100 and 200 µg/0.1 ml (-0.202), INF-γ (-0.293), and IL-10 (-0.249) were relatively dependent, but negative, while IL-12 (0.156), IL-4 (0.227), and CD8+ (0.223) were relatively dependent (Table 2).

Cluster Determinant 25 (CD25+): The ANOVA test showed that the means square of Th2 cytokine (CD8+) between the injection groups...
and as compared to the others (IL-12, INF-γ, IL4, IL-10, CD8+, CD3+, and CD25+) had significant statistical differences, but were very near to it (P=0.097) (Table 1). The amounts of CD3+ were as follows: LB 100 µg/0.1 ml (4.19 pg)<LB 200 (5.18)<control (5.39)<LB T 200 (5.57)<LT 100 (5.75)<LT 200 (5.84)<LBT 100 (6.61). The highest level was related to LBT 100 and the lowest was related to LB 100 (Table 3). Pearson correlation with a two-tailed test of CD4+ with CD3+(0.958), and 0.000 significance, with doses of 100 and 200 µg/0.1 ml (-0.202), IFN-γ (-0.293), and IL-10 (-0.249) were relatively dependent, but negative, while IL-12 (0.156), IL-4 (0.227), and CD8+ (0.223) were relatively dependent (Table 2).

Discussion

In this study, we prepared the L. major antigen as a leishmania vaccine for the third time. According to this topic, we measured the safety, toxicity, and reproducibility in different conditions, and confirmed the authors’ previous results with the same experiments as well as additional ones. Our present results showed that without considering the injection doses, IL-12 had significant differences (P=0.001) and CD4+ had nearly significant differences (P=0.097) among all the groups. INF-γ (P=0.110), CD3+ (P=0.117), and CD8+ (P=0.158) had no significant differences, but were approximately near to it. IL-4 (P=0.506) and IL-10 (P=0.587) showed no significant differences among all the groups (Table 1). In our previous post challenge experiments, IL-12 was found to be significant among all the groups (P=0.008), and IL-4 and IL-10 had no significant differences (P=0.323 and P=0.22) (26). The present Th1 and Th2 cytokine results confirmed our previous findings (21, 23, 24, and 26). This new vaccine increases DTH pre-challenge and leads to an increase of IL-12 in the post-challenge phase. As per the post-challenge results, we did not know whether the challenge with live leishmania promastigote increased IL-12 or if the increase was due to our preliminary vaccine. But we were satisfied to see that the new vaccine induce to production significant immune response which was significant and resistant-in mice against live promastigote with high survival rates have had with high and significantly IL-12 between all of the groups. An important finding for us was that the injections of the new vaccine pre-challenge directly increased IL-12 with different adjuvants, and the two injection doses of 100 and 200 µg/ml showed significant differences between all the injection groups (LB, LT, and LBT) (Table 1). This is an important point for the new vaccine, because not only did IL-12 and IFN-γ increase, but also IL-4 and 10 decreased compared to normal, which suggests that this harmless new vaccine provides an immune defense against intracellular pathogens in Balb/c mice. Now, if our study was reversed, interferon gamma and interleukin 12 would decrease and IL-4 and IL-10 would increase; we had seen this as it was a breach of the vaccine, which had shifted antibodies after exposure to intracellular pathogens (L.) and ultimately fatal visceral leishmaniasis that led to failure of the vaccine. The reason for this is that in this case, the animal model has produced humoral immunity and antibody. But fortunately, this new vaccine has no significant difference in IL-4 production, and 10 injections were observed for any of the two injection doses and three injection groups (Table 1; Graphs 1-4; Figures 1-4) (Figures 7 and 8). In the first study, we measured the delayed type hypersensitivity (DTH), resistant, and susceptible mice before the challenge. We came up with different results for different injection groups, and observed that the new vaccine could not only stimulate the delayed immune system, but it could also be sensitized 48 h after injecting the new antigen, and it turned from negative to positive and the expansion of spleen white pulp size was seen in resistant and
susceptible mice [31-33]. For the second time, the different injection doses and injection groups showed significant differences again for the Th1 and Th2 cytokine profiles, and the expansion of spleen white pulp size in susceptible mice (Balb/c) against the same new vaccine post-challenge with live promastigote [34-36]. With regard to these results, this new vaccine was found to have the ability to stimulate a delayed immune system as well as produce positive DTH 48 h after vaccination [31,33], and the post-challenge increases in IL-12 and IL-10 were significant in some groups [34,36-41]. We had also observed in one of our previous studies that pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), in non-healing, active leishmaniasis patients, and antioxidant levels were higher than in the other three patient and control groups [42]. Lipopolysaccharide Leishmania could suppress TNF-α, IL-1β, and NO production by lipopolysaccharide-stimulated or PMA-stimulated macrophages. TNF-α induces mononuclear phagocytes and neutrophils to produce reactive oxygen intermediates (ROIs) [42], which led us to guess that increased amounts of Th1 cytokines such as IL-12 and IFN-γ cause a high DTH response. In contrast, Th2 cytokine (e.g. IL-4 and IL-10) levels enhanced a low DTH response in cutaneous leishmaniasis [21].

IL-4 and IL-10 act together in the presence of leishmania antigens [43]. When L. major causes a single cutaneous lesion or undergoes a spontaneous cure, the subject is resistant. In this case, probably, the infection was inhibited in the macrophage via innate immunity and production of IFN-γ and IL-12 by a Th1 response that led to the elimination of the parasite. In a future challenge, the subject would most likely be immune [23]. Scott et al. have suggested that low antigen doses may preferably promote a CD4+ Th2 response in vivo, whereas high doses may favor the development of Th1 cells [44]. The results of our present study also confirmed that CD4+ cells had significant differences depending on the two-dose injections and the three-group injections in

Figure 7: Mean of interferon gamma for three injections groups: LB, LT, and LBT with normal group in serum of Balb/c mice after vaccination with new leishmania vaccine.

Figure 8: Mean of interferon gamma for two injections dose: 100 and 200 microgram/0.1 ml with normal group 0.00 microgram /0.1 ml in serum of Balb/c mice after vaccination with new leishmania vaccine.
the pre-challenge phase of the new leishmania vaccine. The most visible disparity with our previous study’s results, though not significantly, was the increase of IL-6 in the non-healing group, irrespective of whether IL-6 and TNF-a increased in the healing and active groups [42]. But an important and interesting point noticed about in vivo immune response (Balb/C) was that the one situation which was ready for innate immune response against intracellular bacteria and parasites pertained to high IL-12 and IFN-γ and low IL-4,10. When intracellular parasites enter the neutrophil, macrophage, or dendritic cells, immediately with the help of IL-12 and IFN-γ loop, the levels of IL-12 and IFN-γ increase, and if the immune system can be successful in this step then leishmaniasis or other intracellular diseases can be limited, and a recovery occurs, and if these cytokines have genetic or any other defects in producing humoral cytokines, including IL-4 and IL-10, then the infection progresses, leading to systemic leishmaniasis. But we still didn’t know that, in our previous studies, after challenge when IL-12 and interferon-gamma gamma increased after exposure, this effect related to pre-exposure vaccination or post challenging with live promastigote [43-44]. All previous articles, as well as the present study, expected that a successful vaccine would increase IL-12 and interferon-gamma. According to the results of all the studies, we answered some of many our questions:

1. We now know that DTH caused by injecting the new vaccine in the first study was re-established with live promastigote [21,23].
2. It subsequently led to a significant increase in IL-12, but significantly decreased IL-10 in some of the groups (see Figures 3 and 4; Table 1).
3. This new vaccine significantly increased IL-12 and decreased IL-10 in the pre-challenge phase, but significantly showed increase in some groups in the post-challenge scenario with live promastigote. This led to an inverse relationship between increased IL-12 and decreased IL-10, and in this study, CD4+ also increased (Table 1).

Our results suggested that increased IL-12 suppressed and prevented the induction of IL-10, and vice versa, IL-12 was suppressed and prevented by IL-10 [24,26].

With regard to our findings, we can propose that, first, the level of Th1 cytokines is high and Th2 is low pertaining to leishmania, but leishmaniasis disrupts its balance and causes its decrease. A successful vaccine must retain this feature, and not allow a decline in Th1 and an increase in Th2. Fortunately, this new vaccine was able to demonstrate this in our present experiments, and our research will continue to study this.

Acknowledgment

This research has been supported by Tehran University of Medical Sciences & health Services grant 14047-30-02-90 (19/5/2011) and 15886-30-02-90 (19/5/2011) and Sciences & health Services grant 14047-30-02-90 (19/5/2011) and 15886-30-02-90 (19/5/2011) and 15886-30-02-90 (19/5/2011). The authors would like to express their gratitude to the members of the Department of Immunology, Research Institute of Medical Sciences, for their logistic support and helpful discussion.

References

1. Eric Dumonteil (2009) Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era. Infect Genet Evol 9: 1075–1082.
2. Guerrant RL, Walker, David DH, Weller PF (2006) Tropical Infectious Diseases: Principles, Pathogens, & Practice (2nd ed.). Philadelphia, PA: Elsevier, Inc. pp. 1095-1113.
3. Allison MJ, Leishmaniasis, Kiple KF (1993) The Cambridge History of Human Disease, Cambridge, Cambridge University Press.
4. Desjeux P, UNAIDS (1998) Leishmania and HIV in gridlock. Geneva, World Health Organization and UNAIDS.
5. Cupollolo E, Medina-Acosta E, Noyes H, Momen H, Grimaldi G Jr (2000) A revised classification for Leishmania and Endotrypanum. Parasitol Today 16: 142-144.
6. Robertson ID, Irwin PJ, Lymbery AJ, Thompson RC (2000) The role of companion animals in the emergence of parasitic zoones. Int J Parasitol 30: 1369-1377.
7. Ferreira WA, Mayrink W, dos Mares-Guia ML, Tavares CA (2003) Detection and characterization of Leishmania antigens from an American cutaneous leishmaniasis vaccine for diagnosis of visceral Leishmaniasis. Diagn Microbiol Infect Dis 45: 35-43.
8. Aamaral VF, Tava A, Oliveira-Neto MP, Silva AJ, Pereira MS, et al. (2002) Study of safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a nesus monkey (Macaca mulata) model of the human disease. Mem Inst Oswaldo Cruz 97: 1041-8.
9. Sharifi I, Fekri AR, Aflatoon MR, Khamesipour A, Nadim A, et al. (1998) Randomized vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous Leishmaniasis in Baram, Iran. Lancet 351: 1540-3.
10. Selvapandian A, Duncan R, Debrabant A, Lee N, Sreenivas G, et al. (2006) Genetically modified live attenuated parasites as vaccines for leishmaniasis. Indian J Med Res 123: 455-466.
11. Campos-Neto (2000) What about Th1/Th2 in cutaneous Leishmaniasis vaccine discovery? Braz J Med Biol Res 33: 979-84.
12. Howard JG, Hale CE, Chan-Hew WL (1980) Immunological regulation of experimental cutaneous Leishmaniasis 1. Immunogenetics aspects of susceptibility to Leishmania tropica in mice. Parasite Immunol 303-14.
13. Guermontrez P, Valladeau J, Zitvogel L, Théry C, Amigorena S (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20: 621-667.
14. Cella M, Scheidegger D, Palmer-Lehman K, Lane p, Lanzavecchia A, et al. (1998) Ligation of CD40 and dendritic cells triggers production of high levels of interferon-12 and enhances T cell stimulatory capacity T-T help via Apacitation. J Exp Med 198: 747-52.
15. Qi H, Denning TL, Soong L (2003) Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial toll-like receptor activators and skewing of T cell cytokine profiles. Infect Imm 71: 3337-42.
16. Stober D, Schirmeck R, Reimann J (2001) IL-12/18-dependent IFN-gamma release by murine dendritic cells. J Immunol 167: 957-965.
17. Quinones M, Agha SK, Melby PC, Pate L, Reddick RI, et al. (2000) Performed membrane-associated stores of interleukin (IL)-12 are a previously unrecognized source of bioactive IL-12 that is mobilized within minutes of contact with an extracellular parasite. J Exp Med 192: 507-16.
18. Kelsall BL, Biron CA, Sharma O, Kaye PM (2002) Dendritic cells at the host-pathogen interface. Nat Immunol 3: 699-702.
19. Goark PM, Engwerda CR, Kaye PM (1998) Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol 28: 687-95.
20. Ghalib HW, Whittle JA, Kubin M, Hashim FA, el-Hassan AM, et al. (1995) IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol 154: 4623-4629.
21. Latifnya A, Mohaghegh Hazrati S (2008) Safety and Toxicity of a New Formulated Leishmania major Vaccine in Animal Model Balb/C and Small White Conventional Laboratory Mice. Turk J Parasitol Derg 32: 103-8.
22. Latifnya A, Mohaghegh Hazrati S (2010) Evaluation of the Effects of a New Formulation of Leishmania Major Antigen in Balb/C and Conventional White Laboratory Mice. J Microbiol Immunol Infect 43: 138-46.
23. Latifnya A, Mohaghegh Hazrati S, Mahmoodi M, Mohabadi M (2009) Study on immunity of Leishmania major new crude antigen as a vaccine against Leishmaniasis in out bred (resistant) and Balb/c (sensitive) mice. AGRS 142-144.
24. Latifnya A, Mohaghegh Hazrati S, Khamsepiou le, Vodjgani M, et al. (2013) Post challenging serum cytokine profile (Th1 & Th2) in the vaccinated mice (Balb/C) with a new formulation of Leishmania major antigen. Türkiye Parazitol Derg 37: 233-240.
25. Latifnya A, Gragatzoule M, Khamsepiou le, Mohammadi MA, KhansaryN (2014) Primary Effects of New Leishmania major Antigen on Balb/mice. J Vaccines Vaccin 5: 6.
26. Latifynia A, Gharagozlou MJ, Mohebali M, Hajjaran H, Khansari N (2015) Th1, Th2 Serum Cytokines and Spleen White Pulp Changes Against Preliminary L. Major Vaccine Injection and Challenge With Live L. Major Promastigotes in Balb/C Mice. J Clin Cell Immunol 8: 533. doi: 10.4172/2155-9899.1000533
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
28. Duncan B, Nazarov–Stoica C, Surls J, Kehl M, Bona S, et al. (2010) Double Negative (CD3+4282) TCRab Splenic Cells from Young NOD Mice Provide Long-Lasting Protection against Type 1 Diabetes. 5: e11427.
29. Viana da Costa A, Huerre M, Delacre M, Auiault C, Corria Costa JM, et al. (2002) IL-10 leads to a higher parasite persistence in a resistant mouse model of leishmania major infection. Parasitol Int 51: 367-79.
30. Padigel UM, Alexander J, Farrell JP (2003) The role of interleukin-10 in susceptibility of Balb/c mice to infection with leishmania Mexicana and leishmania-amazonensis. J Immunol 171: 3705-10.
31. BerberichC, Ramirez-Pineda JR, Hambrecht C, Alter G, Skeiky YA, et al. (2003) Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 170: 3171-3179.
32. Coler RN, Skeiky YA, Bernards k, et al. (2002) Immunization with a polyprotein vaccine consisting of the T-cell antigens thiolspecific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immunol 70: 4215-4225.
33. Manickasingham SP, Edwards AD, Schulz O, Reis E Sousa C (2003) The ability of murine dendritic cell subsets to direct T helper cell differentiation is dependent on microbial signals. Eur J Immunol 33: 101-107.
34. Kane MM, Mosser DM (2001) The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 166: 1141-1147.
35. Tanaka T, HU Li J, Seder RA, Fazekas de st Groth B, Paul WE (1993) IL-4 suppresses IL-2 and interferon ? production by naive T cells stimulated by accessory cell-dependent receptor engagement. Proc Natl Acad Sci USA90: 5914-8.
36. Seder RA, Gazzinelli R, Sher A, Paul WE (1993) Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A 90: 10188-10192.
37. Murray HW, Mauze S, Moreira A L, Kaplan G, et al. (2002) Interleukin-10 in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immunol 70: 6284-93.
38. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP (2001) IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 31: 2848-2856.
39. Gannavaram S, Dey R, Avishek K, Selvapandiyan A, Salotra P, et al. (2014) Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis-discovery-and-implications. Front Immunol 23: 241.
40. Latifynia A, Gharagozlou MJ, Mohebali M, Hajjaran H, Khansari N (2015) Th1, Th2 Serum Cytokines and Spleen White Pulp Changes Against Preliminary L. Major Vaccine Injection and Challenge With Live L. Major Promastigotes in Balb/C Mice. J Clin Cell Immunol 5: 6-281.
41. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynne TA, SacksDL (2001) The role of IL-10 in the persistence of leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194: 1497-1506.
42. Latifynia A1, Khamesipour A, Bokaie S, Khansari N (2012) Antioxidants and proinflamatory cytokines in the sera of patients with cutaneous leishmaniasis. Iran J Immunol 9: 208-214.
43. Roberts MT, Stober CB, McKenzie AN, Blackwell JM (2005) Interleukin-4 (IL-4) and IL-10 colude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection. Infect Immun 73: 7620–8.
44. Boonstra A, Asselin-Paturel C, Gilliet M, Crain C, Trinchieri G, et al. (2003) Flexibility of mouse classical and plasmacytoid-driven dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential Tolllike receptor ligation. J Exp Med 197: 101-9.